Sanders drops subpoena threat against Novo Nordisk  (2024)

Sanders said the company has agreed to an early September hearing where CEO Lars Jørgensen will be the sole witness.

“I enjoyed the opportunity of chatting with Mr. Jørgensen this afternoon and thank him for agreeing to voluntarily testify on a solo panel before the HELP Committee on the high cost of Ozempic and Wegovy in the United States,” Sanders said in a statement.

Sanders had scheduled a vote for early next week on a subpoena to force Doug Langa, chief of Novo Nordisk’s U.S. division, to appear for a hearing.

Sanders launched an investigation in April into the “outrageously high prices” of Ozempic and Wegovy. He questioned why Novo Nordisk charges patients in the U.S. “up to 10 to 15 times more” for those products than their counterparts in other western countries like Canada and Germany.

This is the second time this year Sanders threatened to subpoena drug company executives to get them to testify. He used similar tactics with the CEOs of Merck and Johnson & Johnson.

The health committee hasn’t issued a subpoena in over 40 years.

Letters from Novo Nordisk to Sanders that were reviewed by The Hill showed that Jørgensen was willing to voluntarily testify before the HELP committee but did not wish to be a solo witness.

“We asked that, in accord with your public statements to the New York Times and your statement to Mr. Jørgensen directly, the Committee hold a fair hearing which includes a range of stakeholders that impact what patients pay for GLP-1 medicines in the complex U.S. healthcare ecosystem—rather than focus on just one participant,” a letter dated June 7 read.

In a statement, Sanders said he “looks forward to Mr. Jørgensen explaining why Americans are paying up to ten or 15 times more for these medications than people in other countries.”

CDC warns of disruptions to ADHD meds after $100M fraud arrest

GOP Rep. McMorris Rodgers suggests reforms to boost NIH

Keeping Pharmacy Shelves Filled: Solutions to Address Drug Shortages | June 25 in Washington, D.C. | In person & streaming

Join The Hill for a special discussion on the pharmaceutical supply chain as we discuss the collective goal of preventing drug shortages and, when they are unavoidable, mitigating their impact on patients.

Speakers include:

• Dr. Mark McClellan, director, Duke-Margolis Institute for Health Policy
• Dr. Marta Wosińska, senior fellow, Center on Health Policy, The Brookings Institution
• Michael Kleinrock, lead research director, IQVIA Institute for Human Data Science.

Medicare & Drug Pricing: Time to Think Differently | June 27 in Washington, D.C. | In person & streaming nationally

Effects of the landmark 2022 Inflation Reduction Act (IRA) are beginning to show with many saving on health care costs through Medicare. However, unintended consequences of the bill such as increases in utilization management tactics, shifts in research dollars and more are also beginning to surface. Join The Hill, as we discuss lessons learned from the first round of Medicare direct negotiation and explore improvements going into year two.

Speakers include:

• Dana P. Goldman, University Professor of Public Policy, Pharmacy & Economics, University of Southern California
• Dr. Jennifer Ellis, co-chair, Health & Public Policy Committee, Association of Black Cardiologists & Cardiac Surgeon
• Daneen Sekoni, VP, Policy & Advocacy, Cancer Support Community